Zura Bio Limited logo ZURA - Zura Bio Limited

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 1
BUY 5
HOLD 1
SELL 0
STRONG
SELL 0
| PRICE TARGET: $15.00 DETAILS
HIGH: $15.00
LOW: $15.00
MEDIAN: $15.00
CONSENSUS: $15.00
UPSIDE: 230.40%

Stock News

Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today reported that on May 13, 2026, the Company granted an inducement award consisting of an option to purchase up to 600,000 Class A Ordinary Shares (the “Option”) to Muzammil Mustufa, the Company's new Ch.

May 14, 2026 03:30 AM • businesswire.com
Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer

Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer

HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced the appointment of Muzammil Mustufa as Chief Business Officer (CBO). Mr. Mustufa will oversee corporate strategy, business development, commercial planning, and investor relations efforts. Mr. Mustufa brings.

May 13, 2026 03:30 AM • businesswire.com
Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates

Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates

HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced financial results for the first quarter ended March 31, 2026, and provided recent corporate updates. “We entered the second quarter with a strengthened balance sheet and strengthened team, reflecting growing.

May 07, 2026 03:30 AM • businesswire.com
Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical‑stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today reported that on April 30, 2026, the Company granted inducement awards consisting of options to purchase up to 615,160 Class A Ordinary Shares (the “Options”) to eight newly hired employees. These awar.

May 04, 2026 12:05 PM • businesswire.com
Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates

Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical‑stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today reported financial results for the full year ended December 31, 2025, and provided recent corporate updates. “2025 was a year of strong execution for Zura, marked by meaningful progress across our Phase 2 programs and.

Mar 19, 2026 12:05 PM • businesswire.com
Zura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress

Zura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that the design of its ongoing Phase 2 TibuSURE clinical trial evaluating tibulizumab (ZB-106) in systemic sclerosis (SSc) has been accepted for poster presentation at the Systemic Sclerosis World Congress, t.

Mar 05, 2026 01:30 AM • businesswire.com
Zura Bio to Participate in Upcoming Investor Conferences

Zura Bio to Participate in Upcoming Investor Conferences

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that members of its management team will participate in the following upcoming investor conferences: Leerink Global Healthcare Conference Location: Miami, FL Fireside chat: Tuesday, March 10,.

Mar 02, 2026 01:30 AM • businesswire.com
Zura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Zura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that it closed its previously announced underwritten public offering of Class A ordinary shares and pre‑funded warrants on February 26, 2026. The offering consisted of 21,200,000 Class A ordinary shares price.

Feb 27, 2026 01:30 AM • businesswire.com
Zura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded Warrants

Zura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded Warrants

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced the pricing of its previously announced underwritten public offering of 18,200,000 Class A ordinary shares at a price to the public of $6.25 per share and, in lieu of Class A ordinary shares to certain investors that.

Feb 25, 2026 01:30 AM • businesswire.com
Zura Bio Announces Proposed Public Offering of Class A Ordinary Shares and Pre-Funded Warrants

Zura Bio Announces Proposed Public Offering of Class A Ordinary Shares and Pre-Funded Warrants

HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that it has commenced an underwritten public offering of its Class A ordinary shares or, in lieu of Class A ordinary shares to certain investors that so choose, pre-funded warrants to purchase Class A ordinary shares.

Feb 24, 2026 11:01 AM • businesswire.com
Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D.

Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D.

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced the appointments of Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to its Board of Directors, effective February 21, 2026. As part of this transition, Neil Graham, M.B.B.S., M.D., M.

Feb 23, 2026 01:30 AM • businesswire.com
Zura Bio Highlights Key Phase 2 Tibulizumab Readouts at Guggenheim Biotech Summit 2026

Zura Bio Highlights Key Phase 2 Tibulizumab Readouts at Guggenheim Biotech Summit 2026

Zura Bio (NASDAQ: ZURA) outlined its near-term clinical milestones and strategy at Guggenheim Securities' Emerging Outlook Biotech Summit 2026, emphasizing upcoming Phase 2 readouts for its lead bispecific antibody, tibulizumab, in autoimmune and inflammatory diseases. New CEO highlights shift toward upcoming clinical data Newly appointed Chief Executive Officer Sandeep Kulkarni said he joined the company two

Feb 17, 2026 12:02 AM • defenseworld.net
Zura Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit

Zura Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that its senior leadership team will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit on Wednesday, February 11, 2026, at 11:00 AM ET in New York, NY. The Com.

Feb 04, 2026 01:30 AM • businesswire.com
Zura Bio Appoints Immunology Industry Leader Sandeep Kulkarni, M.D. as Chief Executive Officer

Zura Bio Appoints Immunology Industry Leader Sandeep Kulkarni, M.D. as Chief Executive Officer

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced the appointment of Sandeep Kulkarni, M.D. as Chief Executive Officer (CEO), effective January 21, 2026. Dr. Kulkarni will also continue serving as a Director of Zura. Dr. Kulkarni succeeds Ki.

Jan 21, 2026 03:50 AM • businesswire.com

Price Targets